Lv4
472 积分 2026-05-31 加入
Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma
20天前
已完结
A Plain Language Summary of “Dostarlimab for primary advanced or recurrent endometrial cancer”
20天前
已完结
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma
20天前
已完结
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes
20天前
已关闭
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
20天前
已完结
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes
21天前
已关闭
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
21天前
已完结
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial
21天前
已关闭
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
23天前
已完结
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
24天前
已完结
皖公网安备34019202002308
